Diffuse Malignant Mesothelioma
https://libcat.nshealth.ca/en/permalink/provcat39016
Timothy Craig Allen, editor.
--New York, NY:
Springer
, c2015.
- Available Online
- View e-Book
- Location
- Online
This volume is the most up-to-date text available on diffuse malignant mesothelioma and includes all the newest imaging modalities, immunohistochemical features, and ever-expanding information on the molecular characteristics of the cancer. In-depth chapters contain fully referenced text as well as detailed tables and images. While the primary audiences for this book are pathologists and pathology residents, the broad examination of diffuse malignant mesothelioma, including its epidemiology, ma…
- Available Online
- View e-Book
- Other Authors
- Allen, Timothy Craig
- Responsibility
- Timothy Craig Allen, editor
- Place of Publication
- New York, NY
- Publisher
- Springer
- Date of Publication
- c2015
- Physical Description
- 1 online resource (xi, 142 p. : 56 illus., 46 illus. in color)
- ISBN
- 9781493923748
- 9781493923731 (print ed.)
- Subjects (MeSH)
- Mesothelioma - diagnosis
- Mesothelioma - pathology
- Abstract
- This volume is the most up-to-date text available on diffuse malignant mesothelioma and includes all the newest imaging modalities, immunohistochemical features, and ever-expanding information on the molecular characteristics of the cancer. In-depth chapters contain fully referenced text as well as detailed tables and images. While the primary audiences for this book are pathologists and pathology residents, the broad examination of diffuse malignant mesothelioma, including its epidemiology, makes this book valuable to radiologists, surgeons, oncologists, and other clinical physicians and their residents as well. Written by experts in the field, Diffuse Malignant Mesothelioma is a concise yet comprehensive resource for clinicians involved in the management of one of the most widely recognized and feared cancers in the world.
- Contents
- Approaching the Diagnosis of Diffuse Malignant Mesothelioma -- Epidemiology -- Clinical and Radiologic Features -- Histology -- Immunohistochemistry -- Molecular Characteristics -- Therapy.
- Format
- e-Book
- Location
- Online
Extreme Hepatic Surgery and Other Strategies : Increasing Resectability in Colorectal Liver Metastases
https://libcat.nshealth.ca/en/permalink/provcat41253
Eduardo de Santibañes, Victoria Ardiles, Fernando A. Alvarez, Virginia Cano Busnelli, Martin de Santibañes, editors.
--Cham:
Springer
, 2017.
- Available Online
- View e-Book
- Location
- Online
This book describes the diagnoses; staging and management of patients with colorectal liver metastases initially considered unresectable and portrays the different strategies to increase resectability along with their tactics and tricks. Colorectal carcinoma is the third most commonly diagnosed cancer in the world and according to recent cancer statistics around 1.23 million patients are diagnosed each year. Of these patients, approximately 50% will develop liver metastases during the course of…
- Available Online
- View e-Book
- Other Authors
- de Santibañes, Eduardo
- Ardiles, Victoria
- Alvarez, Fernando A.
- Busnelli, Virginia Cano
- de Santibañes, Martin
- Responsibility
- Eduardo de Santibañes, Victoria Ardiles, Fernando A. Alvarez, Virginia Cano Busnelli, Martin de Santibañes, editors
- Place of Publication
- Cham
- Publisher
- Springer
- Date of Publication
- 2017
- Physical Description
- 1 online resource (xix, 383 pages) : 170 illus., 137 illus. in color
- ISBN
- 9783319138961
- 9783319138954 (print ed.)
- Subjects (MeSH)
- Colorectal Neoplasms - complications
- Liver Neoplasms - secondary
- Liver Neoplasms - surgery
- Abstract
- This book describes the diagnoses; staging and management of patients with colorectal liver metastases initially considered unresectable and portrays the different strategies to increase resectability along with their tactics and tricks. Colorectal carcinoma is the third most commonly diagnosed cancer in the world and according to recent cancer statistics around 1.23 million patients are diagnosed each year. Of these patients, approximately 50% will develop liver metastases during the course of their disease and around 15-25% are found to have stage IV disease at diagnosis. Liver resection has been recognized as the treatment of choice for these patients, offering overall 5-year survival rates of up to 50-60% and the only hope for cure. However, at diagnosis only 10-20% of these patients are possibly amenable to surgical resection with curative intent. The possibility to achieve an R0 resection is many times limited by the amount and quality of the future liver remnant (FLR), being posthepatectomy liver failure (PHLF) the most feared and severe complication after major liver resections. With the years, diverse strategies have been developed with the intention to increase resectability by increasing the future liver remnant and/or reducing tumor size, e.g. ALPPS. Along with these techniques, associated surgeries are developed including multivisceral resections, which broadens even more the resectability for patients.
- Contents
- Part I: Global Patient Evaluation and Oncological Assessment -- 1. Liver Surgical Anatomy -- 2. Resectability Assessment with Diagnostic Imaging -- 3. Preoperative Evaluation of Liver Function -- 4. Imaging-Based Preoperative Planning -- 5. Choosing the Best Strategy -- Part II: Non-operative Multimodal Therapies -- 6. Conversion and Neoadjuvant Therapies -- 7. Portal Vein Embolization -- 8. Intra-Arterial Chemotherapy -- 9. Radioembolization -- Part III: Surgical Strategies -- 10. Anesthetic Management -- 11. Intraoperative Evaluation of Resectability -- 12. Vascular Control in Major Hepatic Resections -- 13. Two-Stage Liver Surgery -- 14. Two-Stage Liver Surgery with Portal Vein Occlusion -- 15. Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) -- 16. Parenchymal-Sparing Liver Resections -- 17. Combined Vascular Resections -- 18. Ex-Vivo Liver Surgery -- 19. The Role of Laparoscopy in Advanced Liver Disease -- 20. Liver Transplantation for Unresectable Disease -- Part IV: Management of Concomitant Extrahepatic Disease -- 21. Lung Metastases -- 22. Nodal Involvement -- 23. Peritoneal Metastases -- 24. Adjacent Organs Invasion: Multivisceral Resections -- Part V: Miscellany -- 25. Postoperative Complications and Their Management -- 26. Improving Quality of Life in Patients with Unresectable Disease.
- Format
- e-Book
- Location
- Online
Management of Chemotherapy-Induced Nausea and Vomiting : New Agents and New Uses of Current Agents
https://libcat.nshealth.ca/en/permalink/provcat40025
Rudolph M. Navari, editor.
(1st ed.)
--Cham:
Springer International Publishing : Imprint: Adis
, c2016.
- Available Online
- View e-Book
- Location
- Online
This book provides a comprehensive review of new agents, a detailed description of new uses of current agents, and an integration of the available agents in clinical practice. A description of a detailed clinical approach provides clinical practitioners with the most up-to-date recommendations for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) in various clinical settings. CINV is one of the most feared treatment related toxicities. Patient surveys for the past …
- Available Online
- View e-Book
- Other Authors
- Navari, Rudolph M
- Responsibility
- Rudolph M. Navari, editor
- Edition
- 1st ed.
- Place of Publication
- Cham
- Publisher
- Springer International Publishing : Imprint: Adis
- Date of Publication
- c2016
- Physical Description
- 1 online resource (viii, 181 p. : 17 illus., 9 illus. in color)
- ISBN
- 9783319270166
- 9783319270142 (print ed.)
- Subjects (MeSH)
- Antiemetics - therapeutic use
- Drug-Related Side Effects and Adverse Reactions
- Nausea - chemically induced
- Nausea - drug therapy
- Neoplasms - drug therapy
- Vomiting - chemically induced
- Vomiting - drug therapy
- Abstract
- This book provides a comprehensive review of new agents, a detailed description of new uses of current agents, and an integration of the available agents in clinical practice. A description of a detailed clinical approach provides clinical practitioners with the most up-to-date recommendations for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) in various clinical settings. CINV is one of the most feared treatment related toxicities. Patient surveys for the past thirty years consistently demonstrate patients' perception of deterioration in quality of life due to chemotherapy treatments. The introduction of the antiemetics, serotonin 5-HT3 receptor antagonists and the neurokinin-1 receptor antagonists, have improved the control of chemotherapy-induced emesis, but the treatment of chemotherapy-induced nausea remains a significant clinical problem. Patients continue to have quality of life issues which prevent normal functioning during active treatment. New agents such as the second generation 5-HT3 receptor antagonist palonosetron and the new neuroknin-1 receptor antagonists rolapitant and netupitant are being introduced into clinical practice, and it is anticipated that these new agents will improve the control of CINV. Agents such as olanzapine (a FDA approved anti-psychotic), gabapentin (a FDA approved neuroleptic), and ginger (a food additive), which have been used primarily for other indications, are now being tested as potential, effective antiemetics. This work represents the first available comprehensive summary that details all new antiemetic agents and, particularly, their clinical role in treating patients; an important reference for practitioners seeking to improve the quality of life of patients undergoing chemotherapy.
- Contents
- 1. Introduction -- 2. The Physiology and Pharmacology of Nausea and Vomiting Induced by Anti-Cancer Chemotherapy in Humans -- 3. First Generation 5HT-3 Receptor Antagonists -- 4. Second Generation Serotonin (5-HT3) Receptor Antagonist Palonosetron -- 5. The Role of Neurokinin-1 Receptor Antagonists in CINV -- 6. Olanzapine for the prevention of Chemotherapy-Induced Nausea and Vomiting -- 7. Gabapentin for the Prevention of CINV -- 8. Prevention of CINV in Patients Receiving High-Dose Multiple-Day Chemotherapy -- 9. Clinical Management of CINV -- 10. Treatment of Chemotherapy-Induced Nausea -- 11. Conclusions -- 12. Future Directions.
- Format
- e-Book
- Location
- Online
